Vertex, NHS trade barbs over CF pricing

NHS England and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) failed to resolve a stalemate over Orkambi lumacaftor/ivacaftor at their latest meeting to discuss reimbursement of the cystic fibrosis drug.

While the two parties released terse statements July 5 in the wake of a meeting on July 4, Vertex spokesperson Heather Nichols did say the company was not considering canceling English trials as it did in

Read the full 629 word article

User Sign In